lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Sublimation is a technique used by chemists to purify compounds. A solid is typically placed in a sublimation apparatus and heated under vacuum. Under this reduced pressure, the solid volatilizes and condenses as a purified compound on a cooled surface (cold finger), leaving a non-volatile residue of impurities behind. Once heating ceases and the vacuum is removed, the purified compound may be collected from the cooling surface. For even higher purification efficiencies, a temperature gradient is applied, which also allows for the separation of different fractions. Typical setups use an evacuated glass tube that is heated gradually in a controlled manner. The material flow is from the hot end, where the initial material is placed, to the cold end that is connected to a pump stand. By controlling temperatures along the length of the tube, the operator can control the zones of re-condensation, with very volatile compounds being pumped out of the system completely (or caught by a separate cold trap), moderately volatile compounds re-condensing along the tube according to their different volatilities, and non-volatile compounds remaining in the hot end. Vacuum sublimation of this type is also the method of choice for purification of organic compounds for use in the organic electronics industry, where very high purities (often > 99.99%) are needed to satisfy the standards for consumer electronics and other applications.
== References == Atmore, Anthony; Sanders, Peter (1971). "Sotho Arms and Ammunition in the Nineteenth Century". The Journal of African History. 12 (4): 535–544. doi:10.1017/S0021853700011130. ISSN 0021-8537. JSTOR 181011. S2CID 161528484. Bradlow, Edna (1970). "General Gordon in Basutoland". Historia. 15 (4): 223–242. ISSN 0018-229X. Retrieved 7 November 2021. Burman, Sandra (1981). Chiefdom Politics and Alien Law: Basutoland under Cape Rule 1871–1884. Palgrave Macmillan. ISBN 978-1-349-04639-3. Eldredge, Elizabeth (2007). Power in Colonial Africa: Conflict and Discourse in Lesotho, 1870–1960. The University of Wisconsin Press. ISBN 978-0-299-22370-0. Kotze, J. (2012). "Counter-Insurgency in the Cape Colony, 1872–1882". Scientia Militaria: South African Journal of Military Studies. 31 (2): 36–58. doi:10.5787/31-2-152. Retrieved 7 November 2021. Machobane, L. B.; Karschay, Stephan (1990). Government and Change in Lesotho, 1800–1966: A Study of Political Institutions. Palgrave Macmillan. ISBN 978-0-333-51570-9. Maliehe, Sean (2014). "An obscured narrative in the political economy of colonial commerce in Lesotho, 1870–1966". Historia. 59 (2): 28–45. hdl:2263/43121. ISSN 0018-229X. Retrieved 7 November 2021. Rosenberg, Scott; Weisfelder, Richard; Frisbie-Fulton, Michelle (2004). Historical Dictionary of Lesotho. The Scarecrow Press. ISBN 0-8108-4871-6. Tylden, G. (1936). "The Basutoland Rebellion of 1880–1881". Journal of the Society for Army Historical Research. 15 (58): 98–107. ISSN 0037-9700. JSTOR 44227993.
RNA polymerase Often abbreviated RNAP or RNApol. Any of a class of polymerase enzymes that synthesize RNA molecules from a DNA template. RNA polymerases are essential for transcription and are found in all living organisms and many viruses. They build long single-stranded polymers called transcripts by adding ribonucleotides one at a time in the 5'-to-3' direction, relying on the template provided by the complementary strand to transcribe the nucleotide sequence faithfully. Unlike DNA polymerases, RNA polymerases notably do not require oligonucleotide primers to initiate synthesis; i.e. they are capable of synthesizing RNA molecules de novo.
Sources: en.wikipedia.org
4-maleylacetoacetate is converted to 4-fumarylacetoacetate, this compound can be broken down into fumarate and acetoacetate by the enzyme fumarylacetoacetate hydrolase. The conversion of 4-maleylacetoacetate to fumarylacetoacetate is a step in the catabolism of phenylalanine and tyrosine, amino acids acquired through dietary protein consumption. When 4-maleylacetoacetate isomerase is unable to function properly, the 4-maleylacetoacetate may be converted instead to succinylacetoacetate and further broken down into succinate and acetoacetate by fumarylacetoacetate hydrolase.
The first β-sheet structure was proposed by William Astbury in the 1930s. He proposed the idea of hydrogen bonding between the peptide bonds of parallel or antiparallel extended β-strands. However, Astbury did not have the necessary data on the bond geometry of the amino acids in order to build accurate models, especially since he did not then know that the peptide bond was planar. A refined version was proposed by Linus Pauling and Robert Corey in 1951. Their model incorporated the planarity of the peptide bond which they previously explained as resulting from keto-enol tautomerization.
He first called for only a pause in fighting, saying that he "doesn't know if a ceasefire is possible with an organization like Hamas", but later called for a humanitarian ceasefire and urged Biden to withhold military aid to Israel. Sanders accused Israel of mass starvation, ethnic cleansing, and extermination. Sanders initially said that allegations of genocide had to be adjudicated by the International Court of Justice, but in September 2025 he said: "The intent is clear. The conclusion is inescapable: Israel is committing genocide in Gaza." Addressing Westminster College in a September 2017 speech, Sanders laid out a foreign policy plan for greater international collaboration, adherence to US-led international agreements such as the Paris Agreement and the Iran nuclear deal framework and promoting human rights and democratic ideals. He emphasized the consequences associated with global economic inequality and climate change and urged reining in the use of US military power, saying it "must always be a last resort". He also criticized US support for "murderous regimes" during the Cold War, such as those in Iran, Chile and El Salvador and said that those actions continue to make the US less safe. He also spoke critically of Russian interference in the 2016 US elections and the way President Trump has handled the crisis. He does not consider Turkey a US ally and condemned the Turkish military offensive against US-aligned Kurdish forces in northeastern Syria.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.